I-Mab (NASDAQ:IMAB - Get Free Report)'s share price rose 0.6% during trading on Thursday . The stock traded as high as $0.86 and last traded at $0.84. Approximately 61,390 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 306,874 shares. The stock had previously closed at $0.84.
Analyst Upgrades and Downgrades
Separately, Brookline Capital Management upgraded I-Mab to a "strong-buy" rating in a research report on Thursday, February 27th.
Check Out Our Latest Research Report on IMAB
I-Mab Stock Performance
The stock's 50-day moving average is $0.94 and its two-hundred day moving average is $1.04.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its position in shares of I-Mab by 140.8% in the third quarter. XTX Topco Ltd now owns 43,039 shares of the company's stock worth $53,000 after buying an additional 25,163 shares in the last quarter. Millennium Management LLC raised its holdings in shares of I-Mab by 763.1% during the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of I-Mab during the 4th quarter valued at approximately $93,000. Cantor Fitzgerald L. P. purchased a new position in shares of I-Mab in the fourth quarter valued at $119,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in shares of I-Mab in the third quarter valued at $179,000. Hedge funds and other institutional investors own 38.38% of the company's stock.
I-Mab Company Profile
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.